BioSante and Cell Genesys encourage stockholders to vote shares

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and Cell Genesys, Inc. (NASDAQ:CEGE), today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended that BioSante and Cell Genesys stockholders vote “FOR” the adoption of the merger agreement between BioSante and Cell Genesys at their upcoming respective special meeting of stockholders scheduled to be held on September 30, 2009.

BioSante and Cell Genesys encourage all stockholders to vote their shares promptly by phone, Internet or by mailing their proxy card. The boards of directors of both companies unanimously recommend that stockholders vote “FOR” the adoption of the merger agreement.

BioSante stockholders in need of assistance voting their shares can call BioSante’s proxy solicitor, Laurel Hill Advisory Group, LLC, toll-free at (888) 742-1305. Cell Genesys stockholders in need of assistance voting their shares can call Cell Genesys’s proxy solicitor, Innisfree M&A Incorporated, toll-free at (800) 750-5833.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer